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ABSTRACT 
Objective: To analyze traits of metabolic syndrome (MetS) in medulloblastoma survivors. 
Subjects and methods: Sixteen childhood medulloblastoma survivors aged 18.0 (4.4) years, 
with history of craniospinal radiation therapy (RT) were compared with nine control subjects 
matched by age, gender, and body mass index, according to fat distribution, metabolic and 
cardiovascular variables. Results: Medulloblastoma patients showed increases in waist circum­
ference and its relationships (all p < 0.05), and HOMA1­IR (p = 0.006), which were modified by 
growth hormone (GH) secretion status. However, these increases were within normal range. 
Conclusions: Adolescent and young adult survivors of medulloblastoma showed centripetal fat 
deposition and decreased insulin sensitivity, associated with GH status. Pediatric brain tumor 
survivors following RT should be monitored for the diagnosis of MetS traits predisposing to 
cardiovascular disease. Arq Bras Endocrinol Metab. 2011;55(8):653-60
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RESUMO
Objetivo: Analisar características que predispõem para síndrome metabólica (SM) em sobrevi­
ventes de meduloblastoma. Sujeitos e métodos: Dezesseis sobreviventes de meduloblastoma 
pediátrico, 18,0 (4,4) anos, história de radioterapia (RT) cranioespinhal, comparados a nove 
controles pareados por idade, sexo e índice de massa corporal, de acordo com distribuição 
de gordura, variáveis metabólicas e cardiovasculares. Resultados: Pacientes com medulo­
blastoma mostraram aumento da cintura e relações (todos p < 0,05) e HOMA1­IR (p = 0,006), 
modificados pela secreção do hormônio de crescimento (GH), mas dentro dos limites de nor­
malidade. Conclusões: Sobreviventes adolescentes e adultos jovens de meduloblastoma apre­
sentaram deposição centrípeta de gordura e diminuição da sensibilidade à insulina, associados 
ao estado do GH. Sobreviventes de tumor cerebral pediátrico que receberam RT devem ser 
monitorados para diagnosticar fatores para SM predispondo à doença cardiovascular. Arq Bras 
Endocrinol Metab. 2011;55(8):653-60
Descritores
Meduloblastoma/terapia; meduloblastoma/quimioterapia; meduloblastoma/radioterapia; medulolastoma/prevenção e 
controle; doenças cardiovasculares; síndrome X metabólica
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Medulloblastoma and metabolic syndrome
INTRODUCTION
Medulloblastoma is one of the most common childhood brain malignancies, accounting for 
approximately 10%-20% of pediatric brain tumors. 
Pediatric tumor types are more sensitive to chemo-
therapy (CT) and to adjuvant radiation therapy (RT), 
compared with adults, and often require high doses of 
craniospinal RT, due to their propensity to dissemi-
nate within the neuraxis (1). Consequently, along with 
the better care provided to pediatric medulloblastoma, 
the spectrum of side effects is broader: RT, particularly 
when combined with CT, brings increased risk of se-
vere long-term after-effects involving neurologic, cog-
nitive, as well as endocrine and metabolic functions 
(2-5). In contrast to other types of tumors, especially 
those of the sellar region (e.g. craniopharyngioma), 
the resulting endocrine and metabolic derangements 
in medulloblastoma are exclusively secondary to ther-
apy damage. 
Post-pediatric cancer survivors, including brain 
tumors, may develop MetS traits due to hormonal 
deficiencies, particularly growth hormone (GH) defi-
ciency, drug or RT damage, endothelial impairment, 
physical inactivity, and/or adipose tissue dysfunction, 
but this issue has not been elucidated yet (6-13). Cra-
nial RT and its consequent hypothalamic dysfunction 
is one of the predisposing mechanisms involved in 
premature cardiovascular disease (CVD), frequently 
described in survivors of pediatric cancers (6). Accor-
ding to a statement developed by the American Heart 
Association along with the Council for Cardiovascular 
Disease in the Young, post-pediatric cancer survivors 
may present increase epidemiological evidence of ma-
nifesting CVD early in adult life, usually after 30 years 
of age (6-8). 
To date, studies that focused on metabolic deran-
gements in childhood medulloblastoma survivors are 
scarce because, despite the advances in therapy regi-
mens, the relapse rate within five years after therapy 
withdrawal is still high. Additionally, previous re-
ports included medulloblastoma among other types 
of pediatric brain tumors with cranial RT (6-8,11-
12). Thus, the purpose of this study was to diffe-
rentiate MetS traits in adolescents and young adult 
survivors of childhood medulloblastoma who were 
followed up in a single center. In addition, it was 
evaluated whether these features were modified by 
GH status.
METHODS
Study population
This cross-sectional study was carried out on a sample 
of male and female medulloblastoma survivors admit-
ted for treatment at the Pediatric Oncology Institute, 
Universidade Federal de São Paulo – Unifesp/EPM, 
São Paulo, Brazil, from February 1990 to August 2005, 
and in normal healthy controls. The study was appro-
ved by the Ethical Research Committee of Unifesp/
EPM, in accordance with the Declaration of Helsinki 
(project no. 1867/06 – Unifesp/EPM). Patients or 
parents, when appropriate, signed an informed consent 
form that allowed participation in this study. 
Medulloblastoma survivors fully completed therapy 
regimens, which encompassed total or partial surgical 
resection, CT, craniospinal RT (24 Gy), and radiothe-
rapy boost (54 Gy). CT was delineated with a combina-
tion of standard drugs comprising: carboplatin, vincris-
tine, ifosfamide, veposide, cisplatin, cyclophosphamide, 
and temozolomide (2-4). Characteristics of host/disea-
se and therapy were assessed from medical records and 
included patient age at diagnosis, time since therapy 
withdrawal, hormonal deficiencies, and therapy em-
ployed. All medulloblastoma subjects were previously 
evaluated in relation to GH secretion status (insulin to-
lerance test, ITT), and GH peak (9,10). They were then 
stratified into two groups for comparison: GH-deficient 
(GHD) and the Non-GHD medulloblastoma survivors, 
whose GH peak was, respectively, lower than or equal 
to 5 μg/L, or over 5 μg/L. Medulloblastoma survivors 
presented complete clinical remission (complete or sub-
total resection, but no evidence of cerebrospinal fluid 
dissemination), completed the treatment protocol, and 
were off therapy for at least two years since diagnosis. 
Survivors and controls were both included in this asses-
sment if they met the following criteria: chronological 
age of 12 years or older; renal, thyroid, gonadal and 
adrenal profiles within the normal range (spontaneous 
or under appropriate hormonal replacement therapy). 
Exclusion criteria were the following therapies and 
conditions: use of anorexigens, insulin-lowering medi-
cations or other drugs interfering with adiposity (e.g. 
metformin, sibutramine, and fluoxetine); exogenous 
human recombinant growth hormone (rhGH) admi-
nistration two years before study enrollment; and bone 
marrow transplantation. The control group presented 
no past medical history, was matched to the medullo-
blastoma group based on age, gender and body mass 
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Medulloblastoma and metabolic syndrome
index (BMI), and was randomly recruited among me-
dical students from the Unifesp/EPM.
Measurements
The following variables were transversally evaluated in 
both medulloblastoma survivors and controls:
Systolic and diastolic blood pressure: supine sys-
tolic and diastolic blood pressure (BP) was measured 
in the right arm using a manual sphygmomanometer 
(Tycos®), and the mean of three measurements, after 
a five-minute rest period, was used. Hypertension was 
defined according to BP cutoff points, as follows: sys-
tolic BP equal or higher than 130 mmHg, and/or dias-
tolic BP equal or higher than 85 mmHg, or use of an-
tihypertensive drug (patients 18 years of age or older) 
(14,15), or systolic and/or diastolic BP equal or higher 
than the 95th percentile for adolescents (16).
Anthropometric variables and body composi-
tion: weight and height were analyzed as Z-scores (Z 
weight and Z height, respectively) (17,18). Final adult 
height was defined as growth speed lower than 1.0 cm 
per year; bone age equal or greater than 14.5 years in 
girls and 16.5 in boys; being fully pubertal, as defined 
by Tanner stage 5 or greater, in boys; and having spon-
taneous menarche, in girls (19,20). Regarding BMI, 
which was calculated as weight divided by height in me-
ters squared (kg/m2), and analyzed as Z-scores, obesity 
was defined as BMI Z-score (Z BMI) > 2.0 standard 
deviation (SD) (17,18).
Total body fat (in percentage, %), lean body mass 
(in kg) and body water (in %) were assessed by means 
of electrical bioimpedance (Model 310 Biodynamics®), 
with patients in supine position, arms and legs away 
from the body. After asepsis of the skin, two electrodes 
were positioned distally and proximally in the right foot 
and hand. The mean of three measurements was used 
in the analysis. Total body fat above the 95th percentile 
was defined as obesity in patients younger than 18 years 
of age (21), and cutoff values based on the National 
Health and Evaluation Survey (NHANES) were used 
for patients 18 years old or older (35.2% and 30.3% for 
females and males, respectively) (22). 
Fat distribution: the following circumferences were 
determined: waist circumference (WC, in cm), hip circu-
mference (HC, in cm), and their relationships: waist-to-
-hip ratio, and waist-to-height ratio. WC and HC were 
measured according to the method described elsewhere 
(23). Regarding WC, the following cutoff values were 
considered for adults: males greater than 102 cm and 
females greater than 88 cm (older than 19 years of age), 
based on the National Cholesterol Education Program 
– Adult Treatment Panel III (NCEP-ATP III) (14); ma-
les 94 cm or greater and females 80 cm or greater (ol-
der than 16 years of age), according to the Internatio-
nal Diabetes Federation (IDF) (15). Cutoff values were 
modified for adolescents as follows: WC equal or greater 
than the 90th percentile (19 years of age or older), ac-
cording to NCEP-ATP III (Cook and cols. study) (24), 
and WC greater than the 90th percentile (16 years of age 
or younger) according to the IDF (25). Data from the 
Bogalusa Study (26) by Freedman and cols. (1999), was 
employed for WC percentiles. A waist-to-height ratio 
above 0.5 indicated visceral adiposity (27). 
Metabolic profile
Lipid panel: total cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglycerides were determined 
using a colorimetric enzymatic method. Low-density li-
poprotein (LDL) cholesterol was calculated by the for-
mula described by Friedewald and cols. (1972) (28). 
In relation to HDL cholesterol and triglycerides, the 
cutoff values proposed by NCEP-ATP III and Cook and 
cols. (14,24), and the IDF (15,25) were considered to 
define dyslipidemia. As for HDL cholesterol levels, ac-
cording to both criteria for adult patients (14,15), the 
cutoff values were below 1.0 mmol/L (males), and be-
low 1.3 mmol/L (females). For adolescents, the cutoff 
values were equal or lower than 1.0 mmol/L (Cook 
and cols. study) (24), and lower than 1.0 mmol/L 
(IDF) (25), for both genders. As for triglyceride levels, 
according to NCEP-ATP III (14) and the IDF (15), 
cutoff values were equal or greater than 1.7 mmol/L 
for adult patients (both genders). For adolescents, the 
cutoff values were equal or greater than 1.2 mmol/L 
(Cook and cols. study) (24), and equal or greater than 
1.7 mmol/L (IDF) (25), for both genders.
Glucose, insulin and insulin sensitivity: fasting 
glucose and insulin levels were assessed using an auto-
mated method. Altered glycemia was defined according 
to Genuth and cols. (29) In order to establish insulin 
sensitivity, glucose and insulin levels were determined 
to calculate the homeostatic model assessment of in-
sulin resistance (HOMA1-IR) (30). HOMA1-IR abo-
ve 2.71 (31) or above 3.16 (32) were determined as 
cutoff levels in adults and adolescents, respectively, to 
define IR. Hyperinsulinemia was defined as an insulin 
level above 173.6 pmol/L. 
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Insulin-like growth factor-1: insulin-like growth 
factor-1 (IGF-1) was analyzed by radioimmunoassay 
after organic solvent extraction and celite column parti-
tion chromatography (33,34). 
Cardiovascular markers
Common carotid artery intima-media thickness: 
common carotid artery (CCA) intima-media thickness 
(IMT) was assessed by ultrasound after a mean of three 
measurements of the posterior wall of the bilateral 
common carotid, 1 cm away from the carotid bifurca-
tion, while patients were in supine position and at rest 
(Toshiba Powervision® with 7-10 MHz vascular linear 
transducer) (33). 
Two-dimensional Doppler echocardiogram: heart 
dimensions and variables related to systolic and diastolic 
function were assessed (Philips EnVisor® version C.1.3, 
with 2.5-3.5 MHz multifrequency transducer). Heart di-
mensions comprised left ventricle (LV) mass (in grams), 
LV mass index (LV mass corrected for body surface area, 
in g/m2), and left atrium (LA, in mm). LV systolic func-
tion variables included ejection fraction (EF, in %), and 
percent shortening (PS, in %); diastolic function variables 
encompassed mitral valve waves E/A ratio, mitral wave 
E deceleration time (msec), and myocardial performance 
index (MPI). EF below 55% and PS below 30% were 
considered as altered LV systolic function (9,33,34).
Statistical analysis
Kolmogorov-Smirnov normality test and Levene test 
were initially conducted to evaluate data distribution and 
group variances. Variables with normal distribution and 
equal variance were presented as means, standard devia-
tions (SD), and 95% confidence intervals (CI). Variables 
that presented non-normal distribution and/or unequal 
variance were transformed into natural logarithm (ln) and 
were presented as medians and ranges (minimum - ma-
ximum). Medulloblastoma and controls were compared 
with respect to quantitative variables using t test for inde-
pendent samples. The subpopulation of GHD medullo-
blastoma subjects was compared with the Non-GHD 
and normal healthy controls, using one-way analysis of 
variance (ANOVA) in relation to the quantitative varia-
bles described. Pairwise comparison test (Tukey’s test) 
was carried out if ANOVA presented p < 0.05. Fisher’s 
exact test was used to evaluate the association between pre-
valence of obesity (as total body fat), centripetal obesity 
(circumferences and relationships), dyslipidemia (HDL 
cholesterol and triglycerides cutoff values), IR (as HO-
MA1-IR cutoff values), and disease/therapy. Alpha level 
was set at 0.05. Statistical analyses were performed using 
SPSS 13.0 (SPSS, Inc., Chicago, IL). 
RESULTS
Study population
From the 81 medulloblastoma patients admitted for 
treatment at the IOP/GRAACC from February 1990 
to August 2005, 48/81 (60%) died or abandoned the-
rapy, and 20/81 (24.7%) were considered eligible for 
this study; four of them refused to participate. The 
study population was made up of 16 medulloblastoma 
survivors aged [mean (SD)] 18.0 (4.0) years, who were 
11.3 (4.5) years old at the time of medulloblastoma 
diagnosis, 5.9 (5.3) years after therapy withdrawal. The 
majority was male (62.5%), 2 patients were prepuber-
tal, and 68.7% had reached final adult height. BMI was 
21.4 (4.2) kg/m2 and Z BMI -0.23 (1.55). The con-
trol sample was composed of 9 subjects aged 20.0 (5.1) 
years, 33.3% males, all pubertal, 66.7% had reached fi-
nal adult height, BMI 21.0 (2.5) kg/m2 and Z BMI 
-0.29 (1.15) SD, as shown in table 1.
Six of the 16 (37.5%) medulloblastoma subjects 
were considered GHD; however, only 1 patient had re-
ceived recombinant human GH (rhGH) for a 2-year 
period. In addition, 7/16 (43.7%) survivors were un-
der levothyroxine sodium replacement therapy, with 
4/16 (25%) showing spinal RT-induced primary hypo-
thyroidism, and 3/16 (18.7%) having post-total thyroi-
Table 1. Clinical and anthropometric data of adolescent and young adult 
survivors of childhood medulloblastoma and normal, healthy controls 
matched by age, gender, and BMI
Variables
Group
Medulloblastoma 
(n = 16)
Control  
(n = 9)
Age at assessment (years) 18.0 (4.4) 20.0 (5.1)
Males 10/16 (62.5%) 3/9 (33.3%)
Age at medulloblastoma 
diagnosis (years)
11.3 (4.5) -
Time post-treatment (years) 5.9 (5.3) -
Final adult height 11/16 (68.7%) 6/9 (66.7%)
BMI (kg/m2) 21.4 (4.2) 21.0 (2.5)
BMI (SD) -0.23 (1.55) -0.29 (1.15)
Data are presented as means (SD) or frequencies. BMI: body mass index, SD: standard deviation.
Medulloblastoma and metabolic syndrome
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dectomy secondary to thyroid nodule (2 patients diag-
nosed with colloid goiter and 1 patient with thyroid 
papillary carcinoma). Three of the 16 (18.7%) patients 
(all females) required hormonal replacement therapy 
due to therapy-induced primary gonadal failure. 
Body composition, fat distribution and insulin 
sensitivity: WC, waist-to-hip ratio and waist-to-height 
ratio were statistically higher in medulloblastoma pa-
tients compared with controls (Table 2). There was a 
trend toward elevation of total body fat in medullo-
blastoma subjects; however, no subject was considered 
obese in BMI analysis. 
Medulloblastoma patients presented higher gluco-
se, insulin and HOMA1-IR when compared with  con-
trols (Table 3); nonetheless, no patient was glucose-
-intolerant or presented with hyperinsulinemia. Three 
of the 16 (18.7%) medulloblastoma subjects presented 
IR. However, there was no association between obesity, 
centripetal obesity, IR and disease/therapy. 
Lipid panel and echocardiographic variables: 
HDL cholesterol and echocardiographic parameters of 
systolic function (EF and PS) were decreased in medullo-
blastoma patients compared with controls (Tables 3 and 
4, respectively). There was no difference in the preva-
lence of dyslipidemia between medulloblastoma patients 
and normal healthy controls, using different criteria. No 
medulloblastoma patient presented alterations in EF. 
Growth hormone status effect on quantitative va-
riables: GH status modified some of the studied outco-
mes, in the comparison of the three groups: GHD (n = 
6), Non-GHD medulloblastoma survivors (n = 10), and 
controls (n = 9), as follows: Z height, waist-to-hip and 
waist-to-height ratios, glucose, HOMA1-IR, and EF 
(ANOVA, p < 0.05). After a multiple comparison test, 
Z height and EF were decreased in GHD, compared 
with Non-GHD medulloblastoma survivors. Waist-to-
-hip and waist-to-height ratios, glucose, and HOMA1-
-IR were increased in GHD medulloblastoma subjects, 
compared with controls (Tukey’s test, all tests p < 0.05). 
Table 2. Blood pressure, anthropometric, body composition and fat 
distribution variables in adolescent and young adult survivors of 
medulloblastoma, compared with normal healthy controls (* p < 0.05)
Variables Medulloblastoma(n = 16)
Control 
(n = 9)
[95% CI  
of the 
difference]
p value
Systolic BP (mmHg) 108.4 (14.4) 106.7 (8.7) [-9.2; 12.7] 
0.752
Diastolic BP (mmHg) 61.6 (56.6 - 80) 60.3 (58.6 – 76.7) -
0.634
Weight Z-score (SD) -0.86 (1.42) -0.44 (1.10) [-1.56; 0.70]
0.449
Height Z-score (SD) -1.28 (1.19) -0.87 (1.34) [-1.49; 0.66]
0.432
Total body fat (%) 22.3 (10.8) 14.9 (9.0) [-1.3; 16.2]
0.093
Lean body mass (kg) 41.6 (13.2) 39.8 (12.3) [-9.3; 12.9]
0.742
Body water (%) 70.9 (6.3) 69.2 (2.5) [-2.8; 6.3]
0.441
WC (cm) 76.8 (10.1) 67.9 (5.6) [1.3; 16.6]
0.024*
HC (cm) 90.3 (10.1) 92.9 (10.2) [-11.3; 6.2]
0.547
Waist-to-hip ratio 0.85 (0.06) 0.74 (0.07) [0.05; 0.16]
0.001*
Waist-to-height ratio 0.50 (0.40 - 0.60) 0.40 (0.40 - 0.50) -
0.018*
Values are expressed as means (SD) [95% CI of the difference] or medians (range); CI: 
confidence interval; SD: standard deviation; BP: blood pressure; WC: waist circumference; HC: 
hip circumference.
Table 3. Metabolic and vascular variables in adolescent and young adult survivors 
of medulloblastoma, compared with normal healthy controls (* p < 0.05)
Variables Medulloblastoma(n = 16)
Control 
(n = 9)
[95% CI  
of the 
difference]
t test  
p value
Total cholesterol 
(mmol/L)
4.4 (0.9) 4.0 (1.6) [-0.7; 1.4]
0.465
LDL cholesterol 
(mmol/L)
2.6 (0.7) 2.3 (0.6) [-0.3; 0.8]
0.357
HDL cholesterol 
(mmol/L)
1.3 (0.4) 1.6 (0.2) [-0.5; 0.0]
0.053
Triglycerides 
(mmol/L)
1.0 (0.7) 0.9 (0.5) [-0.5; 0.6]
0.874
IGF-1 (nmol/L) 34.8 (17.0) 32.3 (8.6) [-10.1; 15.2]
0.682
Glucose (mmol/L) 4.9 (0.5) 4.5 (0.4) [0.0; 0.8]
0.045*
Insulin (pmol/L) 40.3 (13.9 – 121.5) 17.4 (13.9 – 27.0) -
0.002*
HOMA1-IR 1.15 (0.40 – 3.80) 0.40 (0.40 – 0.90) -
0.006*
Right CCA IMT (mm) 0.65 (0.09) 0.61 (0.05) [-0.02; 0.12]
0.191
Left CCA IMT (mm) 0.65 (0.51 – 0.84) 0.63 (0.51 – 0.65) -
0.426
Values are expressed as means (SD) [95% CI of the difference] or medians (range); CI: 
confidence interval; SD: standard deviation; LDL: low density lipoprotein, HDL: high density 
lipoprotein; IGF-1: insulin-like growth factor-1; HOMA1-IR: homeostasis model assessment-
insulin resistance; CCA: common carotid artery; IMT: intima-media thickness.
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increase was within normal limits. Waist-to-height ratio 
is the index that better reflects centripetal deposition 
of fat (27) and has a strong correlation with visceral 
fat evaluated by magnetic resonance imaging, which is 
the gold standard (36). However, we must emphasize 
that waist-to-height ratio should be carefully interpre-
ted in this sample, since GHD medulloblastoma sub-
jects presented decreased Z height, as a consequence 
of spinal RT. Hypothalamic lesion (and GH deficiency) 
secondary to craniospinal RT could possibly be one of 
the main causes of alterations in body fat compartments 
and decreased height in patients treated for medullo-
blastoma (3,4,6,8). That is the reason why current re-
gimens are proposing low doses of craniospinal RT (18 
Gy) to treat nondisseminated medulloblastoma, despi-
te the aggressiveness of the disease, in order to diminish 
endocrine after-effects (37,38). These kind of studies 
are scarce and analyze medulloblastoma together with 
other malignancies. Notwithstanding, the risk of cen-
tral obesity in survivors of childhood cancer, including 
acute lymphocytic leukemia, craniopharyngioma, follo-
wing bone marrow transplantation (BMT), and brain 
tumors with cranial RT history, has already been descri-
bed and concurs with the present study (6-13).
IR is the factor that links all other MetS criteria, 
together with endothelial dysfunction (6,8,36). In this 
study, medulloblastoma survivors showed increased 
insulin secretion, decreased insulin sensitivity, and an 
unfavorable lipid profile. However, to date, these varia-
tions are within normal values. Hyperinsulinemia and 
an adverse lipid profile have been described as an effect 
of therapy in patients treated for various types of cancer 
with adjuvant RT, and after BMT (6,8-11,39). In addi-
tion, GH status was associated with insulin sensitivity 
in this sample.
In relation to CCA IMT, which reflects premature 
asymptomatic atherosclerosis, there was no difference 
between medulloblastoma patients and controls in this 
study, and no association with GH status. On the other 
hand, previous studies have described increased IMT 
in brain tumor survivors and non-oncologic GHD chil-
dren and adolescents (11,33). Furthermore, it is known 
that IMT is positively correlated with RT dosage, and 
negatively correlated with IGF-1 levels which, in turn, 
reflect GH secretion status (6,33,34,40). In the pre-
sent study, the young age of the sample might explain 
the lack of difference between the groups, ever since all 
medulloblastoma patients received high doses of cranial 
RT (54 Gy). Echocardiographic evaluation showed de-
Table 4. Echocardiographic variables in adolescent and young adult 
survivors of medulloblastoma, compared with normal healthy controls (* p 
< 0.05)
Variables Medulloblastoma(n = 16)
Control 
(n = 9)
[95% CI  
of the 
difference]
p value in  
t test
LV mass (g) 85.1 (28.1) 91.5 (19.9) [-28.4; 15.6]
0.553
LV mass index (g/m2) 55.7 (12.7) 59.8 (8.1) [-13.9; 5.7]
0.394
LA (mm) 28.6 (3.2) 30.2 (2.6) [-4.2; 1.0]
0.216
Ejection fraction 
(%)
67.8 (4.2) 72.3 (6.4) [-8.9; -0.1]
0.043*
Percent shortening 
(%)
34.0 (4.3) 37.7 (3.8) [-7.1; -0.02]
0.049*
Mitral valve waves 
E:A ratio
1.76 (0.28) 1.70 (0.31) [-0.20; 0.32]
0.626
Mitral wave E 
deceleration time 
(msec)
180.9 (37.4) 197.2 (25.4) [-46.9; 14.2]
0.279
Myocardial 
performance index
44.0 (20.0 – 87.0) 39.0 (30.0 – 53.0) -
0.556
Values are expressed as means (SD) [95% CI of the difference] or medians (range); CI: 
confidence interval; SD: standard deviation; LV: left ventricle; LA: left atrium.
DISCUSSION
This study investigated whether adolescent and young 
adult survivors of medulloblastoma already present MetS 
traits. The major finding of this study was that some MetS 
traits, such as centripetal fat deposition, altered lipid pro-
file and decreased insulin sensitivity, were detected, at 
a young age, in childhood medulloblastoma survivors 
with history of craniospinal RT, compared with normal 
healthy controls, even though within normal limits so 
far. Additionally, GH status influenced fat distribution 
variables, and insulin sensitivity was also observed.
Adiposity, possibly by means of hyperinsulinism and 
IGF-1, has a role in promoting carcinogenesis and, in 
its turn, carcinogenesis could also contribute to the de-
velopment of MetS in survivors of various malignancies 
(6,35). In this study, body composition was evalua-
ted by electrical bioimpedance, and fat distribution by 
circumferences and their relationships, which are not 
the gold standard methods to date. Nevertheless, total 
body fat showed a trend toward increase, and WC ra-
tios were all increased (particularly in the GHD subpo-
pulation) in medulloblastoma patients, which is in ac-
cordance with previous studies (11), even though this 
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creased systolic function in medulloblastoma subjects, 
and an effect of GH, but without clinical relevance. GH 
is important for cardiac function and contractility, and 
CT (particularly with anthracyclines) may impair this 
function (8,9,12).
The population studied in the present evaluation 
was made up of only 16 medulloblastoma survivors, 
who were off therapy for at least 2 years from diagno-
sis, all treated with CT and craniospinal RT. The small 
size of the sample is due to the fact that medulloblasto-
ma is an extremely aggressive, highly recurrent tumor, 
limiting the population to be studied (1-5). Nonethe-
less, they were compared with matched controls, and 
some differences related to fat distribution and meta-
bolic derangements were evidenced. Although it was 
not the aim of this study, some other factors, rather 
than chronological age, could explain the absence of 
some abnormalities in this subgroup of patients, such 
as shorter post-treatment interval, overprotection, ex-
treme parental health care, and medical support (6). 
In conclusion, patients treated for childhood me-
dulloblastoma at a mean age of 18 years, 5.9 years off 
therapy presented centripetal adiposity, and decreased 
insulin sensitivity, all outcomes modified by GH defi-
ciency. No signs of asymptomatic atherosclerosis were 
detected; however, there were alterations in systolic 
function variables. Medulloblastoma survivors should 
be followed up for early diagnosis of metabolic abnor-
malities, in a way to prioritize interventions and reduce 
the occurrence of CVD between 30-40 years of age, in 
this population.
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